SER-252 — Interim data
Q3 2026
Serina expects that a blinded review of safety and tolerability data from Cohort 1 will support advancement to Cohort 2 in the third quarter of 2026.Source filing
SER biotech catalysts & pipeline
SERINA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
SER-252 — Topline data
H1 2027
Top-line data from the single-ascending-dose arm remain targeted for the first half of 2027.Source filing